Answers are grounded in this paper and cite their sources.
Despite successes with new drug approvals over the past two decades through conventional drug development approaches, many human diseases remain intractable to current therapeutic interventions. Possible barriers may be that the complexity of the target, and disease biology, are impervious to such conventional drug development approaches. The US National Institutes of Health hosted a workshop with the goal of identifying challenges and opportunities with alternative modalities for developing treatments across diseases associated with historically undruggable targets. This report highlights key issues discussed during the workshop that, if addressed, could expand the pool of therapeutic approaches for treating various diseases. Teaser Despite successes with new drug approvals, many human diseases remain intractable to conventional therapeutic interventions. This report highlights areas to expand the pool of therapeutic approaches for treating disease discussed at a recent NIH workshop.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: